Literature DB >> 7505177

The organization of hospital-based home care for terminally ill cancer patients: the Motala model.

B Beck-Friis1, P Strang.   

Abstract

In 1977, the first palliative home care programme in Sweden, the Motala hospital-based home care, was established to provide a high level of medical care on a 24-hour basis, as an alternative and a replacement to hospital care. The current study summarizes the care and organizational needs of 179 consecutive terminally ill cancer patients treated during a 10-year period. Of the patients, 70% came from acute clinics. The median time of care was 36 days. The need for help with activities of daily living was a significant predictor of the length of survival, with the greatest difference between four or less compared to five or six items (p = 0.0006). Analgesics were needed by 96% of the patients, and 78% were provided with various facilities such as hospital beds. The input of family members as primary caregivers was essential for successful care, as were security factors such as easy availability of a nurse or doctor, at any time day or night, and an immediate, guaranteed hospital bed, if needed. As many as 89% of the patients who wished to live at home until death actually did so. We conclude that hospital-based home care according to the Motala model can replace hospital care for selected patients, but only if both the patient and the family approve.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7505177     DOI: 10.1177/026921639300700202

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  12 in total

1.  Predictors of home care expenditures and death at home for cancer patients in an integrated comprehensive palliative home care pilot program.

Authors:  Doris M Howell; Tom Abernathy; Rhonda Cockerill; Kevin Brazil; Frank Wagner; Larry Librach
Journal:  Healthc Policy       Date:  2011-02

2.  Dying cancer patients' experiences of powerlessness and helplessness.

Authors:  Lisa Sand; Peter Strang; Anna Milberg
Journal:  Support Care Cancer       Date:  2007-11-20       Impact factor: 3.603

3.  Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review.

Authors:  F W Smeenk; J C van Haastregt; L P de Witte; H F Crebolder
Journal:  BMJ       Date:  1998-06-27

4.  Brain tumours in Sweden 1996: care and costs.

Authors:  P Blomqvist; J Lycke; P Strang; H Törnqvist; A Ekbom
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

5.  Next of kin's experience of powerlessness and helplessness in palliative home care.

Authors:  Anna Milberg; Peter Strang; Maria Jakobsson
Journal:  Support Care Cancer       Date:  2003-12-18       Impact factor: 3.603

6.  Predictive factors for home deaths among cancer patients in Swedish palliative home care.

Authors:  E Gyllenhammar; E Thoren-Todoulos; P Strang; G Ström; E Eriksson; M Kinch
Journal:  Support Care Cancer       Date:  2003-07-03       Impact factor: 3.603

7.  Support group programme for relatives of terminally ill cancer patients.

Authors:  Asa Witkowski; Maria E Carlsson
Journal:  Support Care Cancer       Date:  2004-03       Impact factor: 3.603

Review 8.  Enabling more dying people to remain at home.

Authors:  G Thorpe
Journal:  BMJ       Date:  1993-10-09

9.  The medical care of patients with primary care home nursing is complex and influenced by non-medical factors: a comprehensive retrospective study from a suburban area in Sweden.

Authors:  Sonja Modin; Anna-Karin Furhoff
Journal:  BMC Health Serv Res       Date:  2004-08-26       Impact factor: 2.655

10.  Can comprehensive specialised end-of-life care be provided at home? Lessons from a study of an innovative consultant-led community service in the UK.

Authors:  B Noble; N King; A Woolmore; P Hughes; M Winslow; J Melvin; J Brooks; A Bravington; C Ingleton; P A Bath
Journal:  Eur J Cancer Care (Engl)       Date:  2014-04-15       Impact factor: 2.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.